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Abstract
Background: Age and number of recipients in need of kidney re-transplantation are increasing. Re-transplantation
practices and outcomes in elderly recipients are not previously explored. We aimed to retrospectively evaluate the
outcomes of recipients 65 years and older receiving their second deceased donor allograft.
Methods: The study was designed as a retrospective registry based study. All recipients 65 years or older who
received a deceased donor kidney transplant at Oslo University Hospital between 2000 and 2014 were included in
the study. Survival outcomes were compared between recipients of first (TX1) and second (TX2) allograft. Survival
analyses were performed using the Kaplan–Meier method and Cox proportional hazard models with patient
survival, uncensored graft survival and death-censored graft survival as outcomes in the analyses.
Results: Seven hundred and thirty-tree recipients > 65 years received a first (n = 687) or second (n = 46) deceased
donor kidney transplant. Five years uncensored graft survival rates were 64% in TX 2 and 67% in TX 1 (P= 0.789).
Estimated five years graft survival rates censored for death with functioning graft were 88% in TX2 and 90% in TX1
(P=0.475). Adjusted hazard ratio for uncensored graft loss (TX2 vs. TX1) was 1.24 (95% CI 0.77 – 2.00). Adjusted hazard
ratio for graft loss censored for death with functioning graft (TX2 vs. TX1) was 1.70 (0.72-4.02).
Conclusions: Older recipients of second transplants have outcomes that are comparable to the outcomes of
age-matched first transplant recipients, and far better than previously documented for older transplant candidates
remaining on dialysis treatment. Advanced age by itself should not be a contraindication for re-transplantation.
Best results are achieved with short time on dialysis before re-transplantation.
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Background
Currently the majority of patients developing end-stage
renal disease (ESRD) whom are eligible for kidney trans-
plantation are between 45 and 65 years of age [1, 2]. A
kidney transplant has an expected half-life of 7–15 years
[3–6]. Consequently, the majority of first time kidney
transplant recipients will later in life be in need of dialy-
sis or re-transplantation. Even though repeat kidney
transplantation have lower expected graft survival com-
pared to first kidney transplantation [7], the life expect-
ancy in a young population is significant better than the
alternative; lifelong dialysis [8]. This benefit is valid
despite the fact that re-transplant recipients present
a higher risk of death during the initial post-
transplant phase [8].
Due to the relative scarcity of available deceased-
donor kidneys, the waiting time is prolonged for most
patients [9] and data from re-transplantation outcomes
will provide important information for allocation pol-
icies. There are several reports supporting transplant-
ation in older patients if they are found eligible [10–15].
An increasing number of patients will, however, be in
their late 60´s and early 70´s when their first graft fails.
Recipients older than 65 years who are in need of a re-
transplantation constitute a unique population. They
often have a history of many years with ESRD prior to
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their first transplantation and then long-term immuno-
suppressive therapy with associated comorbidities.
To the best of our knowledge there is no evidence
available to support or contradict the routine of offering
a second renal allograft to elderly patients with graft-
failure. We believe it is important to explore this issue
both for clinical and policy reasons and consequently we
designed this study to evaluate the survival outcomes of
kidney re-transplantation in patients older than 65 years
and compare them with age- and time-matched first kid-
ney transplant recipients.
Methods
Data from all patients, older than 65 years at time of
transplantation, who received their first or second de-
ceased donor kidney transplant at our center between
2000 and 2014 were included in the study. Outcomes
were compared between first (TX1) and second (TX2)
transplants. Patient and transplant characteristics were
reported prospectively to the Norwegian Renal Registry
and these data were retrieved from the registry together
with survival data. All patients who were included had
previously given consent for the use of their clinical data
in research. Last update of survival data was performed
at September 1st 2015.
Patients accepted for TX1 or TX2 at our center have
been screened using the same age-independent algo-
rithm. The patient´s local nephrologist performs the
screening and we have no need for mandatory dialysis
treatment before the patient can be accepted for the
transplantation wait list. Neither age at first transplant
nor graft survival of first transplant influence the deci-
sion of listing patients for second transplantation. When
allocating a deceased donor kidney, we strive to achieve
some degree of age matching between the donor and the
recipient. As a rule of thumb, we accept a maximal age
difference of 20–30 years. We do not routinely perform
graft nephrectomy prior to re-transplantation.
Between 2000 and 2007, kidney transplant recipients at
our center received a standard triple immunosuppressive
regimen consisting of corticosteroids, Calcineurin in-
hibitor (CNI) with Cyclosprin A (CSA) as first choice,
and either an IL2 receptor antagonist (IL2Rab) for
induction therapy (2000) or mycophenolate mofetil
(MMF) (2001–2007). From 2007 our standard protocol
was changed to a quadruple regimen with IL2Rab induc-
tion, corticosteroids, CNI (tacrolimus or CSA) and MMF.
Statistics
Continuous data were analysed using an independent
sample Mann–Whitney test to compare the groups. A
two-sided Fisher’s exact test was used in analyses of bin-
ary data. Survival analyses were performed using the
Kaplan–Meier method and Cox proportional hazard
models with patient survival, uncensored graft survival
and death-censored graft survival as outcomes in the
analyses. A P-value of less than 0.05 was considered as
significant in all analyses. In the patient survival model,
TX1 patients were censored from the analysis at time of
second transplantation. Available variables with sus-
pected association with the outcome were first tested in
univariable Cox models. Variables with possible associa-
tions, defined as a P-value ≤ 0.2 in the univariable model,
were then included in the final multivariable model.
Recipient age and gender were implemented in all multi-
variable models regardless of the results in the univari-
able model. Except for three recipients with missing
values for cold ischemic time (CIT), there were no miss-
ing values in the dataset for any of the variables included
in the multivariable Cox models. CIT was excluded from
the final model due to very low statistical significance in
the preliminary univariable models. Accordingly, no pa-
tient was excluded from the final multivariable models
because of missing values. All statistical analyses were
performed using the statistical software package IBM
SPSS 23®.
Results
A total of 3812 kidney transplantations were performed
from 2000 to 2014. Eight hundred and sixty-eight (23%)
recipients were 65 years or older at time of first or
second kidney transplant. Among these, 733 patients re-
ceived a deceased donor kidney and were included in the
final analyses. Median age was 70.9 years (range 65.0 -
82.9 years). One hundred and twenty-two patients (16.6%)
received a pre-emptive transplantation, whereas 480
(65.5%) were on hemodialysis (HD) and 131 (17.9%) were
on peritoneal dialysis (PD) at time of engraftment.
Forty-six patients received their second and 687 pa-
tients received their first deceased donor kidney trans-
plant. Eight patients included in the TX2 group received
their first graft between 2000 and 2014 and were at that
time older than 65. They were consequently included in
both groups but censored from the patient survival
model at time of second transplant. Median time be-
tween first and second transplantation was 7.7 years
(range 0.0 – 41.4 years). One patient was re-transplanted
because of primary non-function. If this patient is ex-
cluded, median time between first and second trans-
plantation was 8.2 years (2.5-41.4 years). Patient and
transplant characteristics in TX1 and TX2 are presented
in Table 1. There were some differences between the
groups. We found statistical significant lower median
age of 1.7 years, a lower prevalence of coronary heart
disease and diabetes mellitus, higher prevalence of panel
reactive antibody (PRA) positive B-cell screening and a
trend towards more extensive use of older donors in the
TX2 group. Underlying causes of ESRD are listed in
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Table 2. TX2 patients were also more likely to have
ESRD caused by glomerulonephritis or polycystic kidney
disease and less likely to have vascular nephropathy as
cause of ESRD. The groups were comparable with re-
spect to immunosuppressive therapy (Table 3).
Only five recipients (11%) in the TX2 group experi-
enced a biopsy verified acute rejection episode (ARE)
compared to 140 (20.4%) in the TX1 group. The differ-
ence was however not statistically significant (P = 0.129).
Among those with an ARE, only one out of five recipi-
ents in TX2 experienced the ARE within the first 90
days compared to 86 (61.4%) in TX1. Median time from
transplantation to first ARE was 163 days (21–349) in
TX2 compared to 58.5 days (3–1951) in TX1, but the
difference was not statistically significant (P = 0.190).
During follow-up there were 20 (43%) graft losses in
TX2 and 327 (48%) in TX1. Death with functioning graft
was the predominant cause of graft loss in both groups
being responsible for 14 (70%) graft losses in TX2 and
257 (79%) in TX1. Rejection was the cause of graft loss
in two patients (10%) in TX2 and 31 patients (9.5%) in
TX 1. All other causes were accounted for and because
of low numbers comparisons between groups are of lim-
ited value and were not performed.
Estimated mean patient survival was 7.0 (5.6-8.3)
years in TX2, and 7.6 (7.1-8.1) years in TX1 (Log Rank
P = 0.815). Estimated five-year patient survival was 68%
and 69% in TX2 and TX1 respectively (Fig. 1). Esti-
mated mean uncensored graft survival was 6.7 (5.3-8.1)
years in TX 2 and 7.3 (6.8-7.7) years in TX1 (Log Rank
Table 1 Patient and transplant characteristics. Continuous
variables are reported as median (range)
TX2 (N = 46) TX1 (N = 687) P-value
Age (years) 69.3 (65.1-81.6) 71.0 (65.0-82.9) 0.009
Male recipient 28 (61%) 492 (71.6%) 0.132
Pre-emptive transplantation 6 (13%) 116 (16.9%) 0.682
Coronary heart disease 4 (9%) 190 (27.7%) 0.003
Diabetes mellitus 4 (9%) 152 (22.1%) 0.039
Cerebrovascular disease 4 (9%) 81 (11.8%) 0.641
Peripheral vascular disease 5 (11%) 145 (21.1%) 0.129
Pre-emptive transplantation 6 (13%) 116 (16.9%) 0.682
Hemodialysis 34 (74%) 446 (64.9%) 0.263
Peritoneal Dialysis 6 (13%) 125 (18.2%) 0.550
Time on dialysis (months) 15.5 (0–108) 18.0 (0–87) 0.584
PRA positive B-cell screening 8 (17%) 24 (3.5%) <0.001
CMV positive recipient 43 (94%) 568 (82.7%) 0.065
CMV positive donor 33 (72%) 513 (74.8%) 0.605
Male donor 28 (61%) 387 (56.3%) 0.645
Donor age (years) 64.1 (33.1-85.4) 61.2 (1.6-89.0) 0.106
Donor > 60 years 31 (67%) 364 (53.0%) 0.067
No HLA-A mismatch 13 (28%) 129 (18.8%) 0.124
No HLA-B mismatch 9 (20%) 77 (11.2%) 0.097
No HLA-DR mismatch 20 (44%) 318 (46.3%) 0.761
Cold ischemia time (h) 13.4 (3.8-20.2) 13.9 (2.8-29.0) 0.104
Table 2 Causes of ESRD
TX 2 (N = 46) TX 1 (N = 687) P-value
Glomerulonephritis 17 (37%) 143 (20.8%) 0.016
Pyelonephritis 4 (9%) 31 (4.5%) 0.268
Polycystic kidney disease 15 (33%) 81 (11.8%) <0.001
Vascular nephropathy 5 (11%) 264 (38.4%) <0.001
Diabetes nephropathy 2 (4%) 62 (9.0%) 0.418
Othera 3 (7%) 106 (15.4%) 0.132
a“Other” includes interstitial, hereditary nephropathies, vasculitidis, systemic
disorders, myelomatosis and 14 cases in the TX2 group with unknown cause
of ESRD
Table 3 Immunosuppressive treatment
TX2 (N = 46) TX1 (N = 687) P-value
Induction (IL2R) 36 (78%) 492 (71.6%) 0.398
Prednisolone 46 (100%) 687 (100%) 1.000
Tacrolimus 12 (26%) 187 (27.2%) 1.000
CsA 34 (74%) 476 (69.3%) 0.620
No CNI 0 24 (3.5%) 0.392
MMF* 45 (98%) 646 (94.0%) 0.508
mTOR inhibitor 1 (2%) 14 (2.0%) 1.000
*Thirty patients in TX1 (4.4%) and six patients in TX2 (13%) received
mycophenolic acid. All other patients received mycophenolate
mofetil (p=0.035)
Fig. 1 Estimated patient survival
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P = 0.789). Estimated five year uncensored graft survival
rates were 64% in TX2 and 67% in TX1 (Fig. 2).
Estimated mean death censored graft survival was 9.6
(8.2-11.1) years in TX2 and 13.4 (13.0-13.9) years in
TX1 (Log Rank P = 0.475). Estimated five years graft
survival rates censored for death with functioning graft
were 88% in TX2 and 90% in TX1 (Fig. 3).
In order to adjust for selection bias caused by differ-
ences between TX1 and TX2 in age, donor age, time on
dialysis and comorbidities, a case control dataset consist-
ing of 42 TX1 patients matched with the whole TX2
group (N = 46) by the following variables: age, time on
dialysis, donor age > 60 years and reported prevalence of
coronary heart disease, cerebrovascular disease, periph-
eral vascular disease and diabetes. Matching was per-
formed using the “case control matching” syntax in the
SPSS software. We managed to find only 42 case control
pairs due to the matching variables we selected. The
remaining four TX2 patients were however included in
the analysis as they were all having more comorbidities
than the rest and consequently did not contribute to any
further selection bias in favor of the TX2 group. These
analyses are presented in Table 4 and in Figs. 4, 5 and 6.
Hazard ratio (HR) for uncensored graft loss (TX2 vs.
TX1) adjusted for recipient age, recipient gender, cause
of ESRD, donor age, donor source, time on dialysis, dia-
lysis modality, prevalence of diabetes mellitus, peripheral
vascular disease and HLA matching was 1.24 (95% confi-
dence interval (CI) 0.77-2.00). The unadjusted and ad-
justed Cox models for uncensored graft survival are
presented in Table 5. Recipient age, donor age and time
on dialysis were identified as independent risk variables
for uncensored graft loss whereas IL-2 induction treat-
ment, MMF treatment and glomerulonephritis as cause
of ESRD were associated with improved uncensored
graft survival. Adjusted HR for graft loss censored for
death with functioning graft (TX2 vs. TX1) was 1.70
(0.72-4.02). Donor age, female gender, pre-transplant
diabetes and avoidance of CNI or induction treatment
were identified as independent risk variables for death
censored graft loss.
In a separate uncensored graft loss Cox model analyz-
ing only TX2; age, gender, time on dialysis, donor age
and induction treatment were included in the multivari-
able model based on the results of the univariable ana-
lyses. In this model, only recipient age (HR 1.16, 95% CI
1.03-1.31; P = 0.012) and time on dialysis (HR 1.03, 95%
CI 1.00-1.05; P = 0.02) were significantly associated with
inferior uncensored graft survival. For induction treat-
ment there was a trend towards an association with
Fig. 2 Estimated graft survival
Fig. 3 Estimated graft survival censored for death with
functioning graft
Table 4 Patient and transplant characteristics in the matched
dataset. Continuous variables are reported as median (range).
Survival data are reported as mean survival (95% Confidence
interval)
TX2 (N = 46) TX1 (N = 42) P-value
Age 69.3 (65.1-81.6) 69.5 (65.0-76.1) 0.808
Time on dialysis 15.5 (0–108) 13.5 (0–49) 0.345
Donor > 60 years 31 (67%) 26 (62%) 0.658
Coronary heart disease 4 (9%) 2 (5%) 0.678
Cerebrovascular disease 4 (9%) 2 (5%) 0.678
Peripheral vascular disease 5 (11%) 3 (7%) 0.716
Diabetes mellitus 4 (9%) 0 0.118
Uncensored graft survival 6.7 (5.3-8.1) 7.3 (5.6-9.1) 0.858
Death censored graft survival 9.6 (8.2-11.1) 12.0 (10.6-13.4) 0.555
Patient survival 7.0 (5.6-8.3) 8.0 (6.2-9.8) 0.656
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improved uncensored graft survival (HR 0.32, 95%CI
0.10-1.06, P = 0.062).
Discussion
In patients over 65 years we find no statistical difference
in uncensored or death censored graft survival between
first and second deceased donor kidney transplants. To
the best of our knowledge this is the first study describ-
ing the results of re-transplantation in older recipients.
With an increasing number of previous transplant
recipients with failing grafts, and given the shortage of
deceased donor kidneys, it is important to assess the
outcome of re-transplantation in older recipients.
There was a trend towards higher donor age in the
second transplant group and > 60% received a kidney
from a donor older than 60 years of age i.e. an extended
criteria donor (ECD). In spite of this, in the multivari-
able Cox models we did not find any statistically signifi-
cant increased risk of graft loss in recipients of second
grafts. The number of recipients in the TX 2 group was
however small, and consequently the results must be
interpreted with caution. This is especially true for the
death censored graft loss model in which we found a
statistical non-significant increased risk for graft loss of
70% in TX2 compared with TX1. This increased risk is
definitely of clinical significance, and it is likely that with
a larger sample size, it would reach statistical signifi-
cance as well. It is therefore very likely that the lower
graft survival of second grafts previously described in
adult recipients [7] also is present in older recipients.
On the other hand, TX2 recipients of deceased donor
(DD) grafts had a five years patient survival of 68%,
which is far better than expected for older patients on
dialysis treatment [10, 12] and not different from five
years survival of TX1 recipients. In a study evaluating
325 patients older than 60 years listed for kidney trans-
plantation in Scotland, Oniscu et al. found a life expect-
ancy for patients remaining in dialysis of 4.3 years after
enlisting [16]. Our TX2 patients had an estimated mean
survival of 6.9 years after transplantation.
Kidney re-transplantation has historically, regardless of
recipient age, been associated with a poor prognosis but
still provides the best chance for long-term survival and
Fig. 4 Estimated patient survival, matched dataset
Fig. 5 Estimated graft survival, matched dataset
Fig. 6 Estimated graft survival censored for death with functioning
graft, matched dataset
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quality of life in patients facing allograft loss, as compared
to maintenance dialysis therapy [8, 17–19]. Coupel et al.
compared 233 second transplant recipients with 1174
first transplant recipients and observed no difference in
10-year graft survival [20]. It should be noted that the
second transplant recipients were younger and had a
higher level of HLA-matching than first transplant re-
cipients. This is comparable with our findings even
though we only observed non-significant differences for
HLA-A and HLA-B, but no difference for HLA-DR.
Arnol et al. reported a similar 15-year survival between
81 s transplant recipients compared with 427 first
transplant recipients [21]. A recent large observational
study with 3013 recipients including 641 s transplant
recipients (the French DIVAT cohort) conclude that the
risk of graft failure following a second transplantation
remained consistently higher than that observed in first
transplantation [18]. Contrary to our study, none of
these studies specifically address increasing age at re-
transplantation.
Table 5 Cox uncensored graft loss, uni- and multivariable model
Univariable Multivariable
HR 95% CI P HR 95% CI P
TX2 1.06 0.68-1.67 0.789 1.24 0.77-2.00 0.375
Recipient age 1.07 1.04-1.09 <0.001 1.06 1.03-1.09 <0.001
Male recipient 1.20 0.95-1.53 0.132 1.09 0.85-1.40 0.510
Coronary heart disease 1.15 0.91-1.45 0.247
Diabetes mellitusa 1.21 0.93-1.57 0.160 1.08 0.80-1.45 0.607
Cerebrovascular disease 1.27 0.92-1.75 0.143 1.14 0.81-1.59 0.462
Peripheral vascular disease 1.23 0.96-1.58 0.106 0.97 0.74-1.28 0.840
Time on dialysis (months)b 1.02 1.01-1.02 <0.001 1.02 1.01-1.03 <0.001
Pre-emptive transplantationb 0.74 0.54-1.02 0.063 0.67 0.42-1.08 0.106
HD vs. PD 1.27 0.95-1.70 0.101 1.27 0.83-1.93 0.278
Donor agec 1.02 1.01-1.02 <0.001 1.02 1.01-1.02 <0.001
Donor > 60 yearsc 1.54 1.24-1.91 <0.001 1.57 1.23-2.00 <0.001
Male donor 0.97 0.79-1.20 0.800
CMV positive donor 1.23 0.97-1.58 0.094 1.06 0.81-1.39 0.664
CMV positive recipient 0.81 0.63-1.06 0.119 0.86 0.66-1.13 0.285
Cold ischemia time (CIT) 1.00 0.98-1.02 0.957
Any HLA-A mismatch 0.78 0.60-1.00 0.05 0.73 0.56-0.96 0.025
Any HLA-B mismatch 1.28 0.91-1.80 0.160 1.42 0.98-2.07 0.066
Any HLA-DR mismatch 1.23 0.99-1.51 0.061 1.00 0.79-1.26 0.998
Induction therapy 0.82 0.66-1.03 0.089 0.67 0.52-0.87 0.003
CNI 0.88 0.55-1.42 0.605
CSA vs. Tacrolimus 1.14 0.80-1.64 0.477
MMF 0.77 0.55-1.08 0.123 0.61 0.42-0.90 0.011
mTOR 0.51 0.21-1.24 0.137 0.63 0.26-1.54 0.307
PRA positive 0.93 0.58-1.49 0.752
Any acute rejection 1.11 0.87-1.42 0.393
Glomerulonepritis 0.68 0.53-0.89 0.005 0.63 0.45-0.89 0.008
Pyelonephritis 0.90 0.56-1.47 0.687 0.65 0.37-1.13 0.124
Polycystic kidney disease 0.80 0.58-1.10 0.172 0.68 0.46-1.02 0.064
Vascular nephropathy 1.24 1.00-1.44 0.051 0.87 0.64-1.18 0.373
Diabetes nephropathya 1.31 0.91-1.90 0.151 1.01 0.64-1.59 0.970
aDiabetes and diabetes nephropathy were tested i separate multivariable models. Diabetes was selected in the final model
bPre-emptive transplantation and time on dialysis/dialysis mode were tested in separate multivariable models. In the final model, pre-emptive transplantation
was excluded
cDonor > 60 years and Donor age were tested in separate multivariable models. Only the continuous variable Donor age was included in the final model
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Both DGF and acute rejection episodes are known to
be independent predictors of graft survival [22–24]. An
interesting observation is that acute rejection episodes are
less common and graft survival appears to be improved
when older organs are transplanted to older recipients
[25, 26]. The association between acute rejection and poor
survival has also been demonstrated for recipients of a
second graft [21]. In our cohort, increased immunosup-
pression was clearly identified as protective variables both
in the uncensored (Table 4) and the death censored graft
loss models. In the Cox regression model of the TX2
group, induction therapy with IL2Rab was identified as a
strong (HR 0.32), but only borderline statistically signifi-
cant (P = 0.062), protective variable. In concordance with
this, our results show that with appropriate immunosup-
pression, graft and patient survival is good even in patients
older than 65 years who receive their second transplant.
The main reason for graft loss in both groups was
death with functioning graft. Graft loss due to rejection
was not different between TX2 and TX1, but it must be
noted that the numbers are very low in the TX2 group
making it difficult to draw any firm conclusions. We
were not able to detect any statistically significant differ-
ences in ARE between the groups. The study was how-
ever clearly underpowered to investigate ARE and
additional studies are needed.
As always in observational studies there are several
limitations. The main limitations are the small sample
size, the retrospective design and the use of single centre
data. Single-centre studies often end up including small
numbers giving a low statistical power. Our centre has
had a liberal policy regarding transplantation of the eld-
erly [27]. Consequently we presume that few other
transplant centres can provide a similar number of older
second kidney graft recipients. Single centre studies also
offer homogeneity with respect to medical management.
This can be interpreted as a strength when comparing
outcomes of first and second grafts. An additional
strength is that no recipient was lost to follow-up and
that the data collected from the Norwegian Renal Regis-
try was complete and of superior quality. Further single-
and multicentre studies should be performed to confirm
our findings.
It is quite obvious that patients enlisted for re-
transplantation at age above 65 belong to a selected popu-
lation. We do however use the same age-independent
screening and acceptance criteria for both first and second
transplants. Consequently, those patients who are ac-
cepted for listing are accepted because they are medically
fit for transplantation. In spite of this, TX2 patients had
significantly lower prevalence of coronary heart disease
and diabetes mellitus, indicating that TX2 patients prob-
ably were “more selected” than TX1 patients. It is difficult
to select a proper group for comparison analyses. One
could argue that we should have compared our second
transplant recipients with age-matched recipients with
failing first grafts who were on dialysis. The analyses of
the matched dataset in which TX1 and TX2 patients had
comparable comorbidities, age and time on dialysis did
however not reveal any increased survival difference be-
tween the groups.
In a previous publication we found that 81% of dialysis
patients older than 70 years who were accepted for their
first kidney transplantation, eventually received a graft
[10]. Consequently, the number of patients listed at our
centre for a second transplant who are not receiving a
graft, is very low and comparison using a Cox model
with a time dependent variable (as we have used in a
previous publication [10]) was evaluated as invalid.
Time on dialysis is identified as a significant risk vari-
able for survival both in this study and in previous
studies [28, 29]. Due to the short waiting time at our
centre, our findings may not be fully applicable to other
populations of kidney transplant recipients with longer
waiting times for transplantation, different clinical char-
acteristics or different immunosuppressive regimens.
Conclusions
Older recipients of second transplants have outcomes
that are comparable to the outcomes of age-matched
first transplant recipients, and far better than previously
documented for older transplant candidates remaining
on dialysis treatment. Best results are achieved with
short time on dialysis and consequently, the transplant
work-up should be initiated as soon as possible, prefera-
bly before the patient becomes in need of dialysis.
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